Boehringer Ingelheim

Executive Summary

Boehringer Ingelheim, a global research-driven pharmaceutical company headquartered in Germany, continues to strengthen its leadership in antibodies, biologics, and small molecules while maintaining a long-term, family-owned perspective. The company's diversified portfolio spans human and animal health, with a robust pipeline targeting high-unmet-need areas such as metabolic diseases, oncology, and pulmonary disorders. Key late-stage assets include survodutide, a dual GLP-1/glucagon receptor agonist showing promise in non-alcoholic steatohepatitis (MASH) and obesity, and several oncology candidates leveraging innovative immune-oncology mechanisms. With a commitment to science-driven innovation and a track record of commercial success, Boehringer is well-positioned to sustain growth despite competitive pressures in key therapeutic areas.

Upcoming Catalysts (preview)

• H2 2026Survodutide Phase 3 MASH data readout65% success
• 2027FDA decision on BI 765063 (IL-2 variant) in first-line hepatocellular carcinoma50% success
• Q4 2026Phase 2 results for BI 1820237 (oral GLP-1 agonist) in obesity55% success